The response to CDK4/6 inhibitors in HPV-negative HNSCC patients was favorable.516 HPV-positive HNSCC patients could not benefit from CDK4/6 inhibitors. This evidence concerns the gene CDK4 and head and neck squamous cell carcinoma.